(BSE: 532649 | NSE: NECLIFE)
Chandigarh, January 31, 2025
Nectar Lifesciences Ltd. (NECLIFE) has announced its unaudited financial results for the quarter and nine months ended December 31, 2024. The results were approved in the board meeting held on January 31, 2025.
Key Financial Highlights (Standalone)
| Particulars | Q3 FY25 (₹ in Lacs) | Q2 FY25 (₹ in Lacs) | Q3 FY24 (₹ in Lacs) | 9M FY25 (₹ in Lacs) | 9M FY24 (₹ in Lacs) |
|---|---|---|---|---|---|
| Sales Revenue | 50,412.39 | 49,744.73 | 51,351.66 | 1,41,908.03 | 1,41,414.78 |
| Revenue from Operations | 45,433.44 | 42,788.46 | 45,216.48 | 1,24,106.60 | 1,24,423.82 |
| Total Income | 45,555.51 | 42,878.73 | 45,265.13 | 1,24,419.29 | 1,25,581.86 |
| EBITDA | 4,528.51 | 4,402.27 | 4,267.40 | 13,036.71 | 12,972.04 |
| Profit Before Tax (PBT) | 1,254.78 | 866.61 | 245.65 | 2,613.10 | 715.64 |
| Net Profit (PAT) | 784.04 | 559.89 | 156.69 | 1,640.84 | 440.26 |
| Earnings Per Share (EPS) (₹) | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 |
Key Financial Highlights (Consolidated)
| Particulars | Q3 FY25 (₹ in Lacs) | Q2 FY25 (₹ in Lacs) | Q3 FY24 (₹ in Lacs) | 9M FY25 (₹ in Lacs) | 9M FY24 (₹ in Lacs) |
|---|---|---|---|---|---|
| Revenue from Operations | 45,433.44 | 42,788.46 | 45,216.48 | 1,24,106.60 | 1,24,423.82 |
| Total Income | 45,555.51 | 42,878.73 | 45,265.13 | 1,24,419.29 | 1,25,581.86 |
| Profit Before Tax (PBT) | 1,254.78 | 866.61 | 245.65 | 2,613.10 | 715.64 |
| Net Profit (PAT) | 784.04 | 559.89 | 156.69 | 1,640.84 | 440.26 |
| Earnings Per Share (EPS) (₹) | 0.35 | 0.25 | 0.07 | 0.73 | 0.20 |
Operational Highlights
- Stable Revenue Growth: The company reported a slight increase in total income on a quarter-on-quarter (QoQ) basis. Revenue from operations stood at ₹45,433.44 lakh, reflecting a modest improvement over Q2 FY25.
- Profitability Improvement: The net profit rose to ₹784.04 lakh, showing a substantial increase compared to ₹156.69 lakh in Q3 FY24.
- Cost Management: Total expenses for the quarter stood at ₹44,300.73 lakh, slightly higher than Q2 FY25 but lower than Q3 FY24, indicating improved cost efficiency.
Board Decisions & Corporate Announcements
- Policy Amendments:
- The Board has amended the Policy of Determining Material Subsidiaries and the Materiality of Information Policy in line with the revised SEBI LODR Regulations.
- The updated policies are available on the company’s website: NECLIFE Policies.
- Regulatory Compliance:
- The company designated key personnel for determining materiality of events and disclosures to stock exchanges:
- CEO: Amit Chadah ([email protected])
- Compliance Officer: Neha Vaishnav ([email protected])
- The company designated key personnel for determining materiality of events and disclosures to stock exchanges:
- Board Meeting Details:
- The meeting commenced at 3:30 PM and concluded at 4:30 PM on January 31, 2025.
Management Commentary
Sanjiv Goyal, Chairman & Managing Director of Nectar Lifesciences Ltd., commented:"Our financial performance reflects resilience in a challenging market. While revenue growth remains steady, our focus on operational efficiency has resulted in improved margins and profitability. We continue to strengthen our compliance framework and remain committed to sustainable business practices."
Outlook & Strategic Focus
- R&D Investments: The company remains committed to investing in research and development to enhance its product portfolio.
- Regulatory Compliance: NECLIFE aims to maintain transparency in line with evolving SEBI regulations.
- Growth Strategy: Expansion into new markets and optimization of cost structures remain key priorities.
